Mometazon Doppelherz (Mometasone Furoate Monohydrate)

Mometasone furoate binds to glucocorticoid receptors inside nasal epithelial cells. The drug‑receptor complex moves into the cell nucleus and alters gene expression, suppressing the release of inflammatory cytokines, chemokines, and other mediators. This reduces vascular leakage, edema, and the recruitment of inflammatory cells, leading to decreased nasal inflammation.

The specific dose and frequency of Mometazon Doppelherz are determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and the product label; no universal dosing regimen is provided here.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a low systemic absorption profile, similar to other agents such as fluticasone propionate and budesonide. Compared with lower‑potency options, it may achieve symptom control at a lower daily dose, but individual response and tolerability can vary, so clinicians choose based on patient needs.

Mometazon Doppelherz should be stored at room temperature, typically below 25 °C (77 °F). Keep the spray in its original packaging, protect it from moisture, excessive heat, and direct sunlight to maintain product stability and potency.

The product is a nasal spray intended for intranasal use. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include nasal septal perforation, cataracts or glaucoma with long‑term use, and systemic effects such as adrenal suppression, especially when used together with other systemic corticosteroids. Patients should report any unusual visual changes, persistent nosebleeds, or signs of hormonal imbalance to their healthcare provider promptly.

Mometazon Doppelherz is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active untreated nasal infections, recent nasal surgery involving the septum, or those for whom intranasal corticosteroids are deemed inappropriate by their clinician.